

Stock Data

Share Price:	1.41p
Market Cap:	£15.1m
Shares in issue:	1,072.4m


Company Profile

Sector:	Healthcare
Ticker:	SKIN
Exchange:	AIM

Activities

Integumen plc ('the Group') is a vertically integrated test services company focused on developing and commercialising technology and products that scientifically prove the impact of skin care product claims for healthcare, life sciences, clinical research, pharmaceutical and cosmetics industries.

Share price performance



Source: [LSE](#)

Past performance is not an indication of future performance.

Turner Pope contact details

Turner Pope Investments ("TPI") Limited
8 Frederick's Place
London EC2R 8AB

Tel: 0203 657 0050
Email: info@turnerpope.com
Web: www.turnerpope.com

Attention is drawn to the disclaimers and risk warnings at the end of this document.

This is a non-independent marketing communication. The analyst who has prepared this report is aware that TPI has a relationship with the company covered in this report. Accordingly, it has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

TPI acts as sole broker to Integumen plc.

Retail clients (as defined by the rules of the FCA) must not rely on this document.

Barry Gibb

Research Analyst

Tel: 0203 657 0061
barry.gibb@turnerpope.com

Andrew Thacker

Corporate Broking & Sales

Tel: 0203 657 0050
andy.thacker@turnerpope.com

Zoe Alexander

Corporate Broking & Sales

Tel: 0203 657 0050
zoe.alexander@turnerpope.com

Integumen plc

Application of data-management and AI capabilities to existing core technologies has identified a significant new market opportunity for Integumen and its partners. Rising awareness of the direct impact of climate change on systems vital to the international population's health and wellbeing, the Group's new ecowaterOS platform offers a potential game-changing solution for water monitoring, recovery, treatment and recycling. A consortium led by Rinocloud has successfully integrated water management technologies and systems to address and automate resolution of such challenges into an end-to-end solution that addresses community, regional and even continent-wide demands. This latest initiative highlights foremost the Group's ability to recognise and then rapidly apply modern solutions to help resolve global infrastructural problems, which suggests its principal challenge now could be constructively addressing, as opposed to being overwhelmed by, the scale of the long-term opportunity presented.

Integumen has announced the launch of ecowaterOS ('Ecological Water Operating System'), a green-tech data management eco-system that monitors and analyses water for bacteria contamination using artificial intelligence. ecowaterOS will provide a broad range of clients from water utilities to consumers with real-time alerts regarding the contamination of water supplies and the provision of services from a consortium of water decontamination solution providers.

This initiative has been developed by Rinocloud over the past four years, as it brought together related and highly experienced engineering and software development partners (detailed below) supported by leading-edge research from Cork Institute of Technology and tcBB Resource Centre:

- [Nimbus Research Institute](#) (embedded systems and communications research)
- [Cellulac plc](#)¹ (oil/water separation & solvent free downstream chemical processing)
- [Modern Water plc](#)² (water cleaning, recycling and monitoring solutions provider)
- [Acumen Software](#) (asset and incident management software developer)

Responding to past decades' limited progress in the development of specific water-related applications, frequently hindered by sector fragmentation along with the cost of maintenance of old/out-dated distribution infrastructure, ecowaterOS has been designed specifically with [open source](#), interoperable and [standardised interfaces](#) for both water sector end-users (cities, water utilities, water authorities, citizens and consumers), and solution providers (private utilities, SMEs and regulatory authorities).

Recognising the additional operational pressures today's and other recent commercial moves could possibly place on management, Integumen also announced two new senior appointments. Firstly, at Board level, Fionan (Fin) Murray becomes Chief of Operations; secondly, Paul Ryan is promoted to Chief Sales Officer across all divisions.

Today's news further reflects the opportunity available to companies able to deploy AI and data management technologies that help satisfy the needs of clients in highly demanding and rapidly changing global environments. This has already been highlighted by the surge in demand for Labskin's laboratory data services that have seen Integumen's Board reiterating guidance that anticipates a further, four-fold revenue increase in 2020. Against such a background, further exploitation of Rinocloud's high margin data and AI services, in combination with the analytical/monitoring technologies and customer reach offered through ecowaterOS's multi-continental consortium, highlights the scale of additional opportunity available within the presently underserved global water market. With the weight of anticipated demand from global-scale manufacturers potentially testing the Group's recently expanded laboratory capacity before the current period end, TPI's Initiation research on Integumen plc (released on 8th January 2020) set a target price of 3.23p/share.

¹ Integumen CEO, Mr Gerry Brandon, is also CEO of Cellulac plc; Cellulac plc directly controls 3.56% of Integumen plc voting capital. ² Integumen's CEO, Mr Gerry Brandon, is expected to be appointed as non-executive director and Chairman of the Board of Modern Water plc (AIM:MWG) shortly.

THIS DOCUMENT IS NOT FOR PUBLICATION, DISTRIBUTION OR TRANSMISSION INTO THE UNITED STATES OF AMERICA, JAPAN, CANADA OR AUSTRALIA.

Conflicts

This is a non-independent marketing communication under the rules of the Financial Conduct Authority ("FCA"). The analyst who has prepared this report is aware that Turner Pope Investments (TPI) Limited ("TPI") has a relationship with the company covered in this report. Accordingly, the report has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing by TPI or its clients ahead of the dissemination of investment research.

TPI manages its conflicts in accordance with its conflict management policy. For example, TPI may provide services (including corporate finance advice) where the flow of information is restricted by a Chinese wall. Accordingly, information may be available to TPI that is not reflected in this document. TPI may have acted upon or used research recommendations before they have been published.

Risk Warnings

Retail clients (as defined by the rules of the FCA) must not rely on this document.

Any opinions expressed in this document are those of TPI's research analyst. Any forecast or valuation given in this document is the theoretical result of a study of a range of possible outcomes and is not a forecast of a likely outcome or share price.

The value of securities, particularly those of smaller companies, can fall as well as rise and may be subject to large and sudden swings. In addition, the level of marketability of smaller company securities may result in significant trading spreads and sometimes may lead to difficulties in opening and/or closing positions. Past performance is not necessarily a guide to future performance and forecasts are not a reliable indicator of future results.

AIM is a market designed primarily for emerging or smaller companies and the rules of this market are less demanding than those of the Official List of the UK Listing Authority; consequently AIM investments may not be suitable for some investors. Liquidity may be lower and hence some investments may be harder to realise.

Specific disclaimers

TPI acts as sole broker to Integumen plc ("Integumen") which is listed on the AIM Market of the London Stock Exchange ("AIM"). TPI's private and institutional clients may hold, subscribe for or buy or sell Integumen's securities.

This document has been produced by TPI independently of Integumen. Opinions and estimates in this document are entirely those of TPI as part of its internal research activity. TPI has no authority whatsoever to make any representation or warranty on behalf of Integumen.

General disclaimers

This document, which presents the views of TPI's research analyst, cannot be regarded as "investment research" in accordance with the FCA definition. The contents are based upon sources of information believed to be reliable but no warranty or representation, express or implied, is given as to their accuracy or completeness. Any opinion reflects TPI's judgement at the date of publication and neither TPI nor any of its directors or employees accepts any responsibility in respect of the information or recommendations contained herein which, moreover, are subject to change without notice. Any forecast or valuation given in this document is the theoretical result of a study of a range of possible outcomes and is not a forecast of a likely outcome or share price. TPI does not undertake to provide updates to any opinions or views expressed in this document. TPI accepts no liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection with this document (except in respect of wilful default and to the extent that any such liability cannot be excluded by applicable law).

The information in this document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.

This document is approved and issued by TPI for publication only to UK persons who are authorised persons under the Financial Services and Markets Act 2000 and to professional clients, as defined by Directive 2004/39/EC as set out in the rules of the Financial Conduct Authority. This document may not be published, distributed or transmitted to persons in the United States of America, Japan, Canada or Australia. This document may not be copied or reproduced or re-distributed to any other person or organisation, in whole or in part, without TPI's prior written consent.

Copyright © 2020 Turner Pope Investments (TPI) Limited, all rights reserved.